1. Casper RF, Dodin S, Reid RL, et al. The effect of 20 mcg ethinyl estradiol/1 mg norethindrone acetate (Minestrin™), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause. 1997;4:139-147.
2. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913-920.
3. Friedman AJ, Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol. 1995;85:631-635.
4. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JJ. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986;293:359-362.
5. Parazzini F, Negri E, LaVecchia C, et al. Oral contraceptive use and the risk of fibroids. Obstet Gynecol. 1992;79:430-433.
6. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992;80:708-714.
7. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316:650-655.
8. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152:233-241.
9. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives; a practitioner’s guide to meta-analysis. Human Reprod. 1997;12:1851-1863.
10. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987;257:796-800.
11. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42:497-506.
12. Charreau I, Plu-Bureau G, Bachelot A, Contesso G, Guinebretiere JM, Le MG. Oral contraceptive use and the risk of benign breast disease in a French case-control study. Eur J Cancer Prev. 1993;2:147-154.
13. Gambacciani M, Spinetti A, Cappagli B, et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas. 1994;19:125-131.
14. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Arch Intern Med. 1991;151:1971-1975.
15. Kritz-Silverstein D, Barrett-Connor E. Bone mineral density in post-menopausal women as determined by prior oral contraceptive use. Am J Public Health. 1993;83:100-102.
16. Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC. Oral contraceptives and bone mineral density: a population-based study. Am J Obstet Gynecol. 2000;182:265-269.
17. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol. 2000;95:736-744.
18. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol. 1996;174:15-20.
19. Michaelsson K, Baron JS, Farahmand BY, Fearson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353:1481-1484.
20. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol. 1990;43:1221-1230.
21. Jorgensen C, Picot MC, Bologna C, et al. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996;55:94-98.
22. Fernandez E, LaVecchia C, Francheschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology. 1998;9:295-300.
23. Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst. 1983;71:703-709.
24. Martinez MD, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:1-5.
25. Fernandez E, LaVecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer. 2001;84:722-727.
26. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266.
27. den Tonkelaar I, Oddens SJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357-362.
28. Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil. 1985;30:15-28.
29. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344(20):1527-1534.
30. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. WHO technical bulletin series 877. Geneva: WHO;1998.
31. Tanis BC, Van Der Bosch MAAJ, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345(25):1787-1793.
32. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348:498-505.
33. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke. 1998;29:2277-2284.
34. Chang CL, Donaghy M, Poulter N, et al. Migraine and stroke in young women: case-control study. BMJ. 1999;318:13-18.
35. McKinlay SM, Brambilia DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103-115.
36. Speroff L. Menopause and the perimenopausal transition. In: Clinical Gynecologic Endocrinology and Infertility. 6th edition. Philadelphia, Pa: Lippincott Williams and Wilkins; 1999;643-724.
37. Castracane VD, Gimpel T, Goldzieher JW. When is it safe to switch from oral contraceptives to hormonal replacement therapy? Contraception. 1995;52:371-376.
38. Creinin MD. Laboratory criteria for menopause in women using oral contraceptives. Fertil Steril. 1996;66:101-104.